ESC 365 - Introduction: SGLT2 inhibitors beyond glycemic control.

Open Access

Introduction: SGLT2 inhibitors beyond glycemic control.

Session: SGLT2 inhibition in heart failure: what have we learned so far?

Topic: Heart Failure

Speaker: Doctor S. Zieroth (Winnipeg, CA)

Sponsored by Charité Berlin - Supported by an unrestricted educational grant from The Boehringer Ingelheim and Lilly Alliance

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Shelley Zieroth

University of Manitoba, Winnipeg (Canada)

55 presentations

3 followers

5 more presentations in this session

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Speaker: Professor M. Packer (Dallas, US)

Renal benefits of SGLT2 inhibitors in HF patients.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Effects of SGLT2 inhibitors on quality of life in HF.

Speaker: Professor J. Butler (Dallas, US)

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Speaker: Professor G. Filippatos (Athens, GR)

Conclusion.

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

SGLT2 inhibition in heart failure: what have we learned so far?

Speakers: Doctor S. Zieroth, Professor M. Packer, Professor F. Zannad, Professor J. Butler, Professor G. Filippatos...

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources